HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

XUANZHUBIO-B

63.850

+0.6501.03%

Volume:131.00K

Turnover:8.33M

Market Cap:33.07B

PE:-51.71

High:64.650

Open:62.500

Low:62.500

Close:63.200

52wk High:96.900

52wk Low:23.820

Shares:518.00M

HK Float Shares:160.70M

Volume Ratio:0.72

T/O Rate:0.08%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.235

ROE:--

ROA:--

PB:34.50

PE(LYR):-51.71

PS:913.10

Loading ...

Overview Company News Filings

XuanZhu Bio-B Added to Hang Seng Composite Index, Potential Candidate for Stock Connect

Sihuan Pharmaceutical Expects Significant Profit Growth for 2025

Xuanzhu Biopharmaceutical (02575) Releases Monthly Return for January 2026

Bulletin Express

XuanZhu Bio-B (02575) Surges Over 7% Again as Piroxiclib Tablet Enters National Reimbursement List, Expected to Greatly Enhance Accessibility

Hong Kong Stocks Movement | Xuanzhu Bio-B (02575) Surges Over 6% in Early Trading, Innovative Drug Piroxiclib Set for National Reimbursement on Jan 1, 2026

XuanZhu Bio-B (02575) Appoints Xu Yanjun as General Manager

Xu Yanjun Appointed General Manager of Xuanzhu Biopharmaceutical

XuanZhuBio-B (02575): Dr. Li Ka Kui to Step Down as Executive Director and General Manager

Xuanzhu Biopharmaceutical Executive Director Li Jia Kui Resigns

HK Movers | HK's Biotech Shares Soar. TransThera up 19%; JOINN up 11%; Xuanzhu Bio up 6%

Tiger Newspress

HK Movers | Biomedical Stocks Jump With Xuanzhu Biopharmaceutical up 22%

Tiger Newspress

HK Stock Movement | XUANZHUBIO-B (02575) Surges Over 20% to New High as Xuan Yuening Enters National Reimbursement List and Two Oncology Products Approved Within the Year

Two Oncology Products Approved in 2025: Evaluating XUANZHUBIO-B's (02575) Innovation from a Product Strength Perspective

HK Stock Movement | XUANZHUBIO-B (02575) Rises Nearly 3% as Self-Developed Innovative Drug Xuan Yuening® Included in 2025 National Reimbursement Drug List for the First Time

Xuanzhu Biopharma's Breast Cancer Drug Added to China's 2025 Reimbursement Catalog

MT Newswires Live

China Renews Reimbursement Status for Xuanzhu Biopharma's Ulcer Drug

MT Newswires Live

XUANZHUBIO-B (02575): Innovative Drug Xuan Yuening® Included in 2025 National Reimbursement Drug List for the First Time

Xuanzhu Biopharmaceutical's Anjiuwei Included in 2025 NRDL

Xuanzhu Bio (02575) Publishes Monthly Return on Movements in Securities for November 2025

Bulletin Express

Xuanzhu Biopharmaceutical (2575) Announces Electronic Dissemination of Corporate Communications

Bulletin Express

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/02575/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02575","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02575\",,,,,undefined,":{"symbol":"02575","market":"HK","secType":"STK","nameCN":"XUANZHUBIO-B","latestPrice":63.85,"timestamp":1771214884577,"preClose":63.2,"halted":0,"volume":131000,"delay":0,"changeRate":0.010284810126582255,"floatShares":160701996,"shares":518000000,"eps":-1.234826,"marketStatus":"Closed The third day of Lunar New Year","change":0.65,"latestTime":"02-16 12:08:04","open":62.5,"high":64.65,"low":62.5,"amount":8333700,"amplitude":0.034019,"askPrice":63.95,"askSize":500,"bidPrice":63.25,"bidSize":500,"shortable":0,"etf":0,"ttmEps":-1.178,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1771551000000},"marketStatusCode":7,"adr":0,"listingDate":1760457600000,"exchange":"SEHK","adjPreClose":63.2,"openAndCloseTimeList":[[1771205400000,1771214400000]],"volumeRatio":0.7208196837459873,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02575\",,,,,undefined,":{"symbol":"02575","floatShares":160701996,"roa":"--","roe":"--","lyrEps":-1.234826,"volumeRatio":0.7208196837459873,"shares":518000000,"dividePrice":0,"high":64.65,"amplitude":0.034019,"preClose":63.2,"low":62.5,"week52Low":23.82,"pbRate":"34.50","psRate":"913.10","week52High":96.9,"institutionHeld":0,"latestPrice":63.85,"eps":-1.234826,"divideRate":0,"volume":131000,"delay":0,"ttmEps":-1.178,"open":62.5,"prevYearClose":70.5,"prevWeekClose":63.2,"prevMonthClose":64.35,"prevQuarterClose":70.5,"fiveDayClose":76.55,"twentyDayClose":66.6,"sixtyDayClose":63.8},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02575\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02575\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02575\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02575\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02575","date":"2026-02-16","current":-54.202037,"percent":0.797619,"low":-70.039607,"twenty":-58.54817,"median":-54.4959,"eighty":-52.494765,"high":-22.444691,"avg":-53.738149,"sd":7.501389,"marketCap":33070966391},"quantilePoints":[{"date":"2025-10-17","current":-28.93414,"twenty":-27.261252,"median":-24.751919,"eighty":-23.367582,"marketCap":17558430081},{"date":"2025-10-24","current":-50.850969,"twenty":-50.816841,"median":-33.923646,"eighty":-26.424807,"marketCap":30869688284},{"date":"2025-10-31","current":-54.182971,"twenty":-53.663557,"median":-50.808309,"eighty":-28.95487,"marketCap":32941479444},{"date":"2025-11-07","current":-55.367666,"twenty":-55.639174,"median":-53.630543,"eighty":-30.992132,"marketCap":33640708960},{"date":"2025-11-14","current":-54.36116,"twenty":-55.639174,"median":-54.1994,"eighty":-41.200731,"marketCap":33122761170},{"date":"2025-11-21","current":-53.748657,"twenty":-55.319259,"median":-54.136108,"eighty":-50.782713,"marketCap":32734300328},{"date":"2025-11-28","current":-53.384655,"twenty":-55.070724,"median":-54.15954,"eighty":-50.923112,"marketCap":32630710770},{"date":"2025-12-05","current":-54.773392,"twenty":-55.070724,"median":-54.21583,"eighty":-51.627953,"marketCap":33537119402},{"date":"2025-12-12","current":-70.039607,"twenty":-55.665823,"median":-54.261136,"eighty":-53.311356,"marketCap":42963769180},{"date":"2025-12-19","current":-60.019152,"twenty":-56.570931,"median":-54.488669,"eighty":-53.433833,"marketCap":36903780037},{"date":"2025-12-24","current":-59.160975,"twenty":-59.157371,"median":-54.549256,"eighty":-53.581365,"marketCap":36489421805},{"date":"2026-01-02","current":-54.537602,"twenty":-59.158272,"median":-54.690337,"eighty":-53.655303,"marketCap":33770195908},{"date":"2026-01-09","current":-52.983682,"twenty":-59.049917,"median":-54.49123,"eighty":-52.274882,"marketCap":32889684665},{"date":"2026-01-16","current":-58.758617,"twenty":-58.846722,"median":-54.572443,"eighty":-53.169291,"marketCap":36593011363},{"date":"2026-01-23","current":-52.071916,"twenty":-58.705513,"median":-54.4959,"eighty":-52.506318,"marketCap":32397634264},{"date":"2026-01-30","current":-53.326607,"twenty":-57.909955,"median":-54.48995,"eighty":-52.506318,"marketCap":33329940286},{"date":"2026-02-06","current":-57.283358,"twenty":-57.848985,"median":-54.4959,"eighty":-52.506318,"marketCap":35893781847},{"date":"2026-02-13","current":-51.942748,"twenty":-58.578655,"median":-54.516751,"eighty":-52.506318,"marketCap":32734300328},{"date":"2026-02-16","current":-52.538041,"twenty":-58.54817,"median":-54.4959,"eighty":-52.494765,"marketCap":33070966391}],"updateTime":1771465833649},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02575\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1130834822","title":"XuanZhu Bio-B Added to Hang Seng Composite Index, Potential Candidate for Stock Connect","url":"https://stock-news.laohu8.com/highlight/detail?id=1130834822","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130834822?lang=en_us&edition=fundamental","pubTime":"2026-02-13 19:36","pubTimestamp":1770982579,"startTime":"0","endTime":"0","summary":"On February 13, Hang Seng Indexes Company announced the results of its quarterly review of the Hang Seng Index Series as of December 31, 2025. XuanZhu Bio-B (02575) has been included in the Hang Seng...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSCI","BK1191","02575","VXUS","VT","BK4585","BK4588"],"gpt_icon":0},{"id":"2610629949","title":"Sihuan Pharmaceutical Expects Significant Profit Growth for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2610629949","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610629949?lang=en_us&edition=fundamental","pubTime":"2026-02-10 22:54","pubTimestamp":1770735252,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical Holdings Group Ltd. has issued a positive profit alert for the year, indicating a significant improvement in business performance. The company highlighted that its innovative drug business has entered a harvest period, with subsidiaries Xuanzhu Biopharm and Huisheng Biopharm achieving notable year-on-year revenue growth. Sihuan Pharmaceutical also reported a transition from an investment phase to a revenue-generating phase in its innovative drug segment, leading to a marked enhancement in its profit structure. Additionally, the company noted substantial equity appreciation gains following the successful spin-off listing of Xuanzhu Biopharm and multiple rounds of share repurchases, which have strengthened its financial position and driven breakthroughs in profitability.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDL137MZR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK1515","BK1593","BK1600","00460","BK1191"],"gpt_icon":0},{"id":"1197726114","title":"Xuanzhu Biopharmaceutical (02575) Releases Monthly Return for January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1197726114","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197726114?lang=en_us&edition=fundamental","pubTime":"2026-02-05 17:25","pubTimestamp":1770283535,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. (stock code: 02575) published its Monthly Return for Equity Issuer for the period ended 31 January 2026. According to the report, the total issued share capital...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"gpt_icon":0},{"id":"1124645799","title":"XuanZhu Bio-B (02575) Surges Over 7% Again as Piroxiclib Tablet Enters National Reimbursement List, Expected to Greatly Enhance Accessibility","url":"https://stock-news.laohu8.com/highlight/detail?id=1124645799","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124645799?lang=en_us&edition=fundamental","pubTime":"2026-01-08 15:18","pubTimestamp":1767856717,"startTime":"0","endTime":"0","summary":"XuanZhu Bio-B (02575) surged more than 7% again. As of the time of writing, the stock was up 6.95%, trading at HKD 58.45, with a turnover of HKD 10.7671 million. On the news front, on December 7,...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02575"],"gpt_icon":0},{"id":"1195827868","title":"Hong Kong Stocks Movement | Xuanzhu Bio-B (02575) Surges Over 6% in Early Trading, Innovative Drug Piroxiclib Set for National Reimbursement on Jan 1, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1195827868","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195827868?lang=en_us&edition=fundamental","pubTime":"2026-01-07 09:58","pubTimestamp":1767751102,"startTime":"0","endTime":"0","summary":"Xuanzhu Bio-B (02575) rose more than 6% during the early trading session. As of the time of writing, the stock was up 2.36%, trading at HKD 52.05, with a turnover of HKD 2.9905 million. The catalyst...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","BK1191","06978","02575","159992"],"gpt_icon":0},{"id":"1130506739","title":"XuanZhu Bio-B (02575) Appoints Xu Yanjun as General Manager","url":"https://stock-news.laohu8.com/highlight/detail?id=1130506739","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130506739?lang=en_us&edition=fundamental","pubTime":"2026-01-05 17:53","pubTimestamp":1767606797,"startTime":"0","endTime":"0","summary":"XuanZhu Bio-B (02575) announced that, upon the recommendation of the company's nomination committee, Ms. Xu Yanjun has been appointed as the General Manager of the company, effective January 5, 2026.","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02575"],"gpt_icon":0},{"id":"2601002041","title":"Xu Yanjun Appointed General Manager of Xuanzhu Biopharmaceutical","url":"https://stock-news.laohu8.com/highlight/detail?id=2601002041","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601002041?lang=en_us&edition=fundamental","pubTime":"2026-01-05 17:47","pubTimestamp":1767606462,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co. Ltd. has announced the appointment of Ms. Xu Yanjun as General Manager. Ms. Xu, aged 53, is also the chairperson of the Board and executive Director. She has previously held management positions at Harbin Pacifico Biopharmaceutical Co., Ltd. and Changchun BCHT Biotechnology Co., and holds degrees from Heilongjiang University of Chinese Medicine and Jilin University.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on January 05, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDLbQbJJD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK1515","BK1191","BK0057","BK1600","02575","000661","BK0075","BK0028","BK1593","00460","BK0188","BK0046","688276"],"gpt_icon":0},{"id":"1176425731","title":"XuanZhuBio-B (02575): Dr. Li Ka Kui to Step Down as Executive Director and General Manager","url":"https://stock-news.laohu8.com/highlight/detail?id=1176425731","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176425731?lang=en_us&edition=fundamental","pubTime":"2026-01-02 16:48","pubTimestamp":1767343693,"startTime":"0","endTime":"0","summary":"XuanZhuBio-B (02575) announced that Dr. Li Ka Kui will resign from his positions as an executive director and the general manager of the company to dedicate more time to other business commitments....","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02575"],"gpt_icon":1},{"id":"2600461054","title":"Xuanzhu Biopharmaceutical Executive Director Li Jia Kui Resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2600461054","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600461054?lang=en_us&edition=fundamental","pubTime":"2026-01-02 16:39","pubTimestamp":1767343150,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co. Ltd. announced that Dr. Li Jia Kui has resigned as executive director and general manager to focus on other business commitments. His resignation will take effect upon the appointment of a new executive director by the company's general meeting. The company is actively seeking a suitable replacement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on January 02, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nNDL10lkz3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1600","02575","BK1593","BK1191","00460","BK1515"],"gpt_icon":0},{"id":"1189029586","title":"HK Movers | HK's Biotech Shares Soar. TransThera up 19%; JOINN up 11%; Xuanzhu Bio up 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1189029586","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189029586?lang=en_us&edition=fundamental","pubTime":"2025-12-17 11:43","pubTimestamp":1765943020,"startTime":"0","endTime":"0","summary":"Hong Kong’s biotech stocks rose on Wednesday.TransThera rose 19%; JOINN rose 11%; Xuanzhu Bio up 6%; Remegen, Wuxi Bio up 2%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"56cee07d353081b3259b34f98f1a012b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","02617","06127"],"gpt_icon":0},{"id":"1123300626","title":"HK Movers | Biomedical Stocks Jump With Xuanzhu Biopharmaceutical up 22%","url":"https://stock-news.laohu8.com/highlight/detail?id=1123300626","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123300626?lang=en_us&edition=fundamental","pubTime":"2025-12-12 10:25","pubTimestamp":1765506351,"startTime":"0","endTime":"0","summary":"Biomedical stocks jumped in Hong Kong. Xuanzhu Biopharmaceutical rose 22%; Joinn Laboratories rose 11%; Jacobio Pharmaceuticals rose 6%; CStone Pharmaceuticals rose 5%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"7432cf6f68b776bebe5e689173bcab7f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06127","02616","02575","01167"],"gpt_icon":0},{"id":"1108401237","title":"HK Stock Movement | XUANZHUBIO-B (02575) Surges Over 20% to New High as Xuan Yuening Enters National Reimbursement List and Two Oncology Products Approved Within the Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1108401237","media":"Stock News","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108401237?lang=en_us&edition=fundamental","pubTime":"2025-12-12 10:14","pubTimestamp":1765505655,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B (02575) surged over 20%, hitting a record high of HK$93.05. At the time of writing, the stock was up 19.51% to HK$92.5, with a turnover of HK$18.78 million. The rally follows the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"7432cf6f68b776bebe5e689173bcab7f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02575"],"gpt_icon":0},{"id":"1113008814","title":"Two Oncology Products Approved in 2025: Evaluating XUANZHUBIO-B's (02575) Innovation from a Product Strength Perspective","url":"https://stock-news.laohu8.com/highlight/detail?id=1113008814","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113008814?lang=en_us&edition=fundamental","pubTime":"2025-12-12 08:54","pubTimestamp":1765500877,"startTime":"0","endTime":"0","summary":"The global biotech sector continues to evolve amid the interplay of rational capital allocation and innovative fervor, while China's pharmaceutical industry undergoes a profound reassessment of...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK1191"],"gpt_icon":0},{"id":"1175287814","title":"HK Stock Movement | XUANZHUBIO-B (02575) Rises Nearly 3% as Self-Developed Innovative Drug Xuan Yuening® Included in 2025 National Reimbursement Drug List for the First Time","url":"https://stock-news.laohu8.com/highlight/detail?id=1175287814","media":"Stock News","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175287814?lang=en_us&edition=fundamental","pubTime":"2025-12-10 13:47","pubTimestamp":1765345632,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B (02575) rose nearly 3%, reaching a 1.98% increase at the time of writing, trading at HK$66.95 with a turnover of HK$15.20 million. On December 8, the company announced that its...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK1574","BK1161","06978","BK1191","159992"],"gpt_icon":0},{"id":"2589389096","title":"Xuanzhu Biopharma's Breast Cancer Drug Added to China's 2025 Reimbursement Catalog","url":"https://stock-news.laohu8.com/highlight/detail?id=2589389096","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589389096?lang=en_us&edition=fundamental","pubTime":"2025-12-08 13:46","pubTimestamp":1765172819,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical  said its breast cancer therapy Xuanyuening has been included for the first time in China's 2025 national reimbursement catalog, according to a Monday Hong Kong bourse filing.The CDK2/4/6 inhibitor, approved in May 2025 for HR+/HER2- advanced or metastatic breast cancer, enters the program with both its monotherapy and combination-therapy indications, the filing said.The company will continue to expand hospital coverage and core market penetration as reimbursement takes effect on Jan. 1, 2026, it added.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02575","BK1191"],"gpt_icon":0},{"id":"2589389948","title":"China Renews Reimbursement Status for Xuanzhu Biopharma's Ulcer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2589389948","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589389948?lang=en_us&edition=fundamental","pubTime":"2025-12-08 13:29","pubTimestamp":1765171761,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical (HKG:2575) said its innovative drug Anjiuwei will remain on China's National Reimbursement Drug List in 2025, according to a Monday Hong Kong bourse filing.Anjiuwei, approved in June 2023 for duodenal ulcers, was first added to the list in December 2023.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02575","BK1191"],"gpt_icon":0},{"id":"1179396099","title":"XUANZHUBIO-B (02575): Innovative Drug Xuan Yuening® Included in 2025 National Reimbursement Drug List for the First Time","url":"https://stock-news.laohu8.com/highlight/detail?id=1179396099","media":"Stock News","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179396099?lang=en_us&edition=fundamental","pubTime":"2025-12-08 12:16","pubTimestamp":1765167404,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B (02575) announced that its self-developed innovative drug, Palociclib Tablets (brand name: Xuan Yuening®), has been included in the National Reimbursement Drug List (NRDL) for Basic...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK1574","06978","159992","BK1161","BK1191"],"gpt_icon":0},{"id":"2589385469","title":"Xuanzhu Biopharmaceutical's Anjiuwei Included in 2025 NRDL","url":"https://stock-news.laohu8.com/highlight/detail?id=2589385469","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589385469?lang=en_us&edition=fundamental","pubTime":"2025-12-08 12:09","pubTimestamp":1765166975,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co. Ltd. announced the successful renewal and continued inclusion of its innovative drug, Anjiuwei , in the 2025 National Reimbursement Drug List for Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance , effective from January 1, 2026. This follows a medical insurance renewal with the National Healthcare Security Administration . Anjiuwei, the first and only independently developed proton pump inhibitor in China, was approved in June 2023 for the treatment of duodenal ulcers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kon","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL2b7QW2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NHC","BK1191","02575","BK1593","00460","BK1515","BK1600","BK4185"],"gpt_icon":0},{"id":"1129606503","title":"Xuanzhu Bio (02575) Publishes Monthly Return on Movements in Securities for November 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1129606503","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129606503?lang=en_us&edition=fundamental","pubTime":"2025-12-04 16:59","pubTimestamp":1764838797,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. (stock code: 02575) released its monthly return on movements in securities for the period ending November 30, 2025. According to the report, the total issued share...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"gpt_icon":0},{"id":"1114585748","title":"Xuanzhu Biopharmaceutical (2575) Announces Electronic Dissemination of Corporate Communications","url":"https://stock-news.laohu8.com/highlight/detail?id=1114585748","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114585748?lang=en_us&edition=fundamental","pubTime":"2025-11-20 16:50","pubTimestamp":1763628658,"startTime":"0","endTime":"0","summary":"On 21 November 2025, Xuanzhu Biopharmaceutical Co., Ltd. (2575) released an announcement outlining its adoption of electronic dissemination for corporate communications in accordance with Rule 2.07...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":51,"code":"91000000","status":"200"}]}}